Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.
Purity:
95.00%
CAS Number:
[1428935-60-7]
Target:
PD-1/PD-L1
T11126
T11126
* VAT and and shipping costs not included. Errors and price changes excepted
